Models of type 2 diabetes

Drug Discovery Today: Disease Models

Volumn 2, Issue 3, 2005, Pages 183-189

  Somwar, Romel ^a   Fang, Xiangping ^b   Sweeney, Gary ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CARRIER PROTEIN; FATTY ACID TRANSPORT PROTEIN 1; FATTY ACID TRANSPORT PROTEIN 4; MALONYL COENZYME A; UNCLASSIFIED DRUG;

ANAMNESIS; ARTICLE; CORRELATION ANALYSIS; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE MODEL; DRUG DESIGN; DRUG TARGETING; ENVIRONMENTAL FACTOR; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HEREDITY; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN FUNCTION; RISK FACTOR; TRANSGENIC MOUSE;

EID: 26944446556     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2005.08.011     Document Type: Review

References (45)

1. B.B. Kahn Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance Cell 92 1998 593-596
2. D.A. Rees and J.C. Alcolado Animal models of diabetes mellitus Diab. Med. 22 2005 359-370
3. L. Plum et al. Transgenic and knockout mice in diabetes research: Novel insights into pathophysiology, limitations, and perspectives Physiology (Bethesda) 20 2005 152-161
4. A. Nandi et al. Mouse models of insulin resistance Physiol. Rev. 84 2004 623-647
5. F. Mauvais-Jarvis et al. Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance Clin. Endocrinol. (Oxf.) 57 2002 1-9
6. B.B. Kahn and J.S. Flier Obesity and insulin resistance J. Clin. Invest. 106 2000 473-481
7. Z.T. Bloomgarden Diabetes complications Diab. Care 27 2004 1506-1514
8. M.L. Reitman et al. Lipoatrophy revisited Trends Endocrinol. Metab. 11 2000 410-416
9. E.E. Kershaw and J.S. Flier Adipose tissue as an endocrine organ J. Clin. Endocrinol. Metab. 89 2004 2548-2556
10. A.R. Nawrocki and P.E. Scherer The delicate balance between fat and muscle: Adipokines in metabolic disease and musculoskeletal inflammation Curr. Opin. Pharmacol. 4 2004 281-289
11. S. Ristevski Making better transgenic models: Conditional, temporal, and spatial approaches Mol. Biotechnol. 29 2005 153-163
12. J.W. Kemnitz and G.A. Francken Characteristics of spontaneous obesity in male rhesus monkeys Physiol. Behav. 38 1986 477-483
13. M. Kabir et al. Molecular evidence supporting the portal theory: A causative link between visceral adiposity and hepatic insulin resistance Am. J. Physiol. Endocrinol. Metab. 288 2005 E454-E461
14. S. Tang et al. Decreased in situ insulin receptor dephosphorylation in hyperglycemia-induced insulin resistance in rat adipocytes Diabetes 50 2001 83-90
15. E. Mannucci et al. Plasma adiponectin and hyperglycaemia in diabetic patients Clin. Chem. Lab. Med. 41 2003 1131-1135
16. F. Vasseur et al. The genetics of adiponectin Curr. Diab. Rep. 3 2003 151-158
17. M.E. Trujillo and P.E. Scherer Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome J. Intern. Med. 257 2005 167-175
18. A.H. Berg et al. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism Trends Endocrinol. Metab. 13 2002 84-89
19. N. Maeda et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Nat. Med. 8 2002 731-737
20. N. Kubota et al. Disruption of adiponectin causes insulin resistance and neointimal formation J. Biol. Chem. 277 2002 25863-25866
21. T. Yamauchi et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects Nature 423 2003 762-769
22. C.M. Steppan and M.A. Lazar The current biology of resistin J. Intern. Med. 255 2004 439-447
23. A. Fukuhara et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin Science 307 2005 426-430
24. J. Phan and K. Reue Lipin, a lipodystrophy and obesity gene Cell Metab. 1 2005 73-83
25. E.E. Blaak Fatty acid metabolism in obesity and type 2 diabetes mellitus Proc. Nutr. Soc. 62 2003 753-760
26. V. Large et al. Metabolism of lipids in human white adipocyte Diab. Metab. 30 2004 294-309
27. R.H. Unger Lipid overload and overflow: Metabolic trauma and the metabolic syndrome Trends Endocrinol. Metab. 14 2003 398-403
28. J.J. Luiken et al. Skeletal muscle fatty acid transport and transporters Int. J. Sport Nutr. Exerc. Metab. 11 Suppl. 2001 S92-S96
29. A. Bonen et al. Regulation of fatty acid transport by fatty acid translocase/CD36 Proc. Nutr. Soc. 63 2004 245-249
30. A. Stahl A current review of fatty acid transport proteins (SLC27) Pflugers Arch. 447 2004 722-727
31. J.K. Kim et al. Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle J. Clin. Invest. 113 2004 756-763
32. K. Gertow et al. Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance Diabetologia 47 2004 1118-1125
33. R.E. Gimeno et al. Targeted deletion of fatty acid transport protein-4 results in early embryonic lethality J. Biol. Chem. 278 2003 49512-49516
34. T. Herrmann et al. Mice with targeted disruption of the fatty acid transport protein 4 (Fatp 4, Slc27a4) gene show features of lethal restrictive dermopathy J. Cell Biol. 161 2003 1105-1115
35. C.T. Coburn et al. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice J. Biol. Chem. 275 2000 32523-32529
36. J.R. Goudriaan et al. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice J. Lipid Res. 44 2003 2270-2277
37. T. Hajri et al. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice J. Clin. Invest. 109 2002 1381-1389
38. A. Ibrahimi et al. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin J. Biol. Chem. 274 1999 26761-26766
39. L. Heron-Milhavet et al. Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice Endocrinology 145 2004 4667-4676
40. H.J. Harwood Jr. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome Curr. Opin. Invest. Drugs 5 2004 283-289
41. L. Abu-Elheiga et al. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets Proc. Natl. Acad. Sci. U S A 100 2003 10207-10212
42. W. Oh et al. Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice Proc. Natl. Acad. Sci. U S A 102 2005 1384-1389
43. H.J. Harwood Jr. et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals J. Biol. Chem. 278 2003 37099-37111
44. B. Viollet et al. Physiological role of AMP-activated protein kinase (AMPK): Insights from knockout mouse models Biochem. Soc. Trans. 31 Pt 1 2003 216-219
45. T. Kitamura et al. Mosaic analysis of insulin receptor function J. Clin. Invest. 113 2004 209-219